Galectin Therapeutics Inc. (GALT) Financial Analysis & Valuation | Quarter Chart
Galectin Therapeutics Inc. (GALT)
GALTPrice: $2.79
Fair Value: 🔒
🔒score
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysacc... more
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and ... more
Description
Shares
| Market Cap | $179.88M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Joel Lewis |
| IPO Date | 2002-09-04 | CAGR | — |
| Employees | 15 | Website | galectintherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.12% | Total Yield | -0.12% |
GALT chart loading...
Fundamentals
Technicals
| Enterprise Value | $381.85M | P/E Ratio | -5.36 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -1.41 |
| P/CF Ratio | -7.47 | P/FCF Ratio | -7.53 |
| EPS | $-0.59 | EPS Growth 1Y | -36.84% |
| EPS Growth 3Y | -51.02% | EPS Growth 5Y | 16.39% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | 0.26% | ROA | -1.58% |
| ROCE | — | Current Ratio | 2.42 |
| Quick Ratio | 2.42 | Cash Ratio | 2.21 |
| Debt/Equity | -1.06 | Interest Coverage | — |
| Altman Z Score | -29.58 | Piotroski Score | 2 |